|
| N-(5-chloro-2-methoxyphenyl)-2-(7-methyl-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-3-yl)acetamide |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
| N-(5-chloro-2-methylphenyl)-2-(4-oxo-3(4H)-quinazolinyl)acetamide |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
| N-[(FURAN-2-YL)METHYL]-N'-{1-[4-(4-METHOXYPHENYL)PIPERAZIN-1-YL]-1-(THIOPHEN-2-YL)PROPAN-2-YL}ETHANEDIAMIDE |
|
Mycobacterium |
Exoenzyme |
Preclinical (in vitro) |
Chen L, et al. 2010. ACS Med Chem Lett |
|
| N-benzyl-4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine |
|
Mycobacterium
Staphylococcus |
Biofilm
Biofilm |
Preclinical (in vitro)
Preclinical (in vitro) |
Huggins WM, et al. 2018. ACS Med Chem Lett; Zeiler MJ, et al. 2020. ChemMedChem; Brackett SM, et al. 2020. RSC Med Chem
|
|
| 1-[2-[(4-fluorophenyl)methylamino]-2-oxo-ethyl]-N-[1-(4-methyl-5-vinyl-1H-imidazol-2-yl)ethyl]-6-oxo-pyridine-3-carboxamide |
|
Mycobacterium |
Exoenzyme |
Preclinical (in vitro) |
Mori M, et al. 2014. Bioorg Med Chem Lett |
|
| S-(2,4-difluorophenyl) 2-[5-[4-(trifluoromethyl)phenyl]tetrazol-2-yl]ethanethioate |
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
| 3-{[4-(dimethylamino)-2-pyridin-3-yl-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]carbonyl}phenol |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
Compound 4a
(internal name in literature) |
|
Mycobacterium |
Biofilm |
Preclinical (in vitro) |
Zeiler MJ, et al. 2020. ChemMedChem |
|
Compound 4b
(internal name in literature) |
|
Mycobacterium |
Biofilm |
Preclinical (in vitro) |
Zeiler MJ, et al. 2020. ChemMedChem |
|
Compound 4c
(internal name in literature) |
|
Mycobacterium |
Biofilm |
Preclinical (in vitro) |
Zeiler MJ, et al. 2020. ChemMedChem |
|
| | | |
